Hemostasis News and Research RSS Feed - Hemostasis News and Research

Hemostasis or haemostasis is a complex process which causes the bleeding process to stop. Most times this includes the changing of blood from a fluid to a solid state. Intact blood vessels are central to moderating blood's tendency to clot.
Novel biomarkers may offer solution for detecting autologous blood transfusion in athletes

Novel biomarkers may offer solution for detecting autologous blood transfusion in athletes

Increasing oxygen delivery to muscles can help athletes perform better and give them the edge needed to win elite competitions. One of the best ways to increase oxygen supply is through blood manipulation, undergoing a blood transfusion that provides extra red blood cells and boosts oxygen levels. [More]
Essential Medical receives CE Mark approval for novel vascular closure device

Essential Medical receives CE Mark approval for novel vascular closure device

Essential Medical, Inc., a privately held medical device company addressing the rapidly growing large bore vascular closure market, announced today that it has received CE Mark approval for MANTA, the company's Large Bore Vascular Closure Device. [More]
UNC professor identifies research priorities to address VTE in cancer patients

UNC professor identifies research priorities to address VTE in cancer patients

More than 20 percent of all blood clots in veins occur in cancer patients. These clots, also known as venous thromboembolism (VTE), pose serious threats for cancer patients. [More]
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
Reasons for life-threatening blood clots in elite athletes

Reasons for life-threatening blood clots in elite athletes

Mary Cushman, M.D., M.Sc., a professor of medicine and director of the Thrombosis and Hemostasis Program at the University of Vermont, provides commentary on the causes of life-threatening blood clots in elite athletes. [More]
Researchers identify possible genetic basis for coronary artery disease

Researchers identify possible genetic basis for coronary artery disease

For many people, coronary artery disease, or CAD—the buildup of plaque in the heart's arteries—is an unfortunate part of aging. By studying the genetic makeup of those who manage to maintain clear arteries into old age, researchers have identified a possible genetic basis for the disease, as well as potential new opportunities to prevent it. [More]
New study sheds light on challenges in addressing post-operative bleeding in newborns

New study sheds light on challenges in addressing post-operative bleeding in newborns

A new study finds significant differences between the blood clot structure in adults and newborns, helping researchers better understand the challenges in addressing post-operative bleeding in neonatal patients. [More]
Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings. [More]
Wyss Institute scientists develop better assay for testing hemostasis

Wyss Institute scientists develop better assay for testing hemostasis

Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University have devised a better assay for testing blood's clotting tendency, also known as hemostasis, which could one day prove lifesaving in a variety of clinical situations in which a patient's health is jeopardized by abnormal blood coagulation and platelet function. [More]
New $8.5M research grant aims to address patients affected by severe hemophilia A

New $8.5M research grant aims to address patients affected by severe hemophilia A

People with hemophilia have prolonged abnormal bleeding as a result of trauma. Hemophilia A, also called factor VIII (FVIII) deficiency, is the most common form of the genetic disorder caused by missing or defective blood clotting protein called factor VIII. [More]
IL obtains 510(k) clearance for ACL TOP Family 50 Series Hemostasis Testing Systems

IL obtains 510(k) clearance for ACL TOP Family 50 Series Hemostasis Testing Systems

Instrumentation Laboratory today announced the 510(k) clearance of their latest innovation, the ACL TOP Family 50 Series Hemostasis Testing Systems, by the US Food and Drug Administration. [More]
Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company. [More]
New Swabbable Needleless Injection Sites with Barbs from Qosina

New Swabbable Needleless Injection Sites with Barbs from Qosina

Qosina is pleased to announce the addition of three new barbed swabbable needleless injection sites (#80209-#80211), in stock and ready for immediate delivery. [More]
New model of arterial thrombus formation is similar to popular video game

New model of arterial thrombus formation is similar to popular video game

A group of biophysicists, including representatives from MIPT, has developed a mathematical model of arterial thrombus formation, which is the main cause of heart attacks and strokes. [More]
Olympus introduces EZDilate balloon dilator for improved control in endoscopic balloon dilation procedures

Olympus introduces EZDilate balloon dilator for improved control in endoscopic balloon dilation procedures

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today its new 510(k) cleared EZDilate multi-stage endoscopic balloon dilator for improved precision and control in endoscopic balloon dilation procedures. [More]
New Berman Airways from Qosina

New Berman Airways from Qosina

Qosina is pleased to announce the addition of a new line of Berman Airways (#50114 - #50121), in stock and ready for immediate delivery. [More]
Negative impact of high-fat diet on red blood cells may promote development of cardiovascular disease

Negative impact of high-fat diet on red blood cells may promote development of cardiovascular disease

University of Cincinnati researchers have discovered the negative impact a high fat diet has on red blood cells and how these cells, in turn, promote the development of cardiovascular disease. [More]

BMBF provides EUR 25 million to support CTH's Integrated Research and Treatment Centers program

An international committee of experts has reviewed and recommended the funding of the Center for Thrombosis and Hemostasis at the Mainz University Medical Center for an additional five years. In accordance with this recommendation, the German Federal Ministry of Education and Research will be providing support of approximately EUR 25 million to the CTH within its Integrated Research and Treatment Centers (IFB) program. [More]
Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States. [More]
Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada. [More]
Advertisement
Advertisement